Page last updated: 2024-11-04

3-hydroxybenzylhydrazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-hydroxybenzylhydrazine: decarboxylase inhibitor; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1663
CHEMBL ID352205
CHEBI ID104133
SCHEMBL ID160617
MeSH IDM0045311

Synonyms (47)

Synonym
unii-a27k5q85r2
a27k5q85r2 ,
bdbm50049260
BB 0261819
BRD-K66416915-300-01-2
DIVK1C_006881
SPECTRUM_000313
brn 1841459
nsd 1015
3-(hydrazinomethyl)phenol
m-hydroxybenzyl hydrazine
3-hydroxybenzylhydrazine
hydrazine, 1-(3-hydroxybenzyl)-
lopac-h-9382
NCGC00015524-01
SPECTRUM5_001883
BSPBIO_002252
nsd-1015
KBIO3_001472
KBIO2_003361
KBIO2_000793
KBIOGR_001618
KBIOSS_000793
KBIO2_005929
KBIO1_001825
SPECTRUM3_000726
SPECTRUM4_001209
SPECPLUS_000785
LOPAC0_000597
NCGC00162200-01
637-33-2
3-hydrazinomethyl-phenol
CHEMBL352205 ,
3-(hydrazinylmethyl)phenol
CHEBI:104133
CCG-204686
AKOS015951046
NCGC00015524-02
gtpl5116
SCHEMBL160617
OFKWWALNMPEOSZ-UHFFFAOYSA-N
3-(hydrazinomethyl)phenol #
DTXSID20213099
Q27073730
D87672
PD049693
EN300-270834

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" All of these effects of ATR were observed at levels that were not toxic to the tissue, as LDH release into the medium (lactate dehydrogenase, an index of non-specific cytotoxicity) was not affected by ATR."( Dopaminergic toxicity of the herbicide atrazine in rat striatal slices.
Carr, RL; Filipov, NM; Sistrunk, SC; Stewart, MA, 2007
)
0.34

Bioavailability

ExcerptReferenceRelevance
" Thus, to the extent that somatodendritic DA release affects behavior, TH regulation in the midbrain may be critical for DA bioavailability to influence behavior."( Dichotomy of tyrosine hydroxylase and dopamine regulation between somatodendritic and terminal field areas of nigrostriatal and mesoaccumbens pathways.
Pruett, BS; Salvatore, MF, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
"2 mg/kg) of apomorphine reduced locomotion in a dose-dependent manner, while the reduction after higher doses was less pronounced, indicating a biphasic dose-response relationship."( Catecholamine receptor agonists: effects on motor activity and rate of tyrosine hydroxylation in mouse brain.
Strömbom, U, 1976
)
0.26
" Dose-response curves to quinpirole were unchanged in D(3) knock-out tissue, but secretion-regulated release exhibited a Hill slope decreased to 1 in the wild-type animals."( Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors.
Budygin, EA; Caron, MG; Gainetdinov, RR; Joseph, JD; Miles, PR; Picetti, R; Wang, YM; Wightman, RM, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (26)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency31.62280.007215.758889.3584AID411
15-lipoxygenase, partialHomo sapiens (human)Potency12.58930.012610.691788.5700AID887
NFKB1 protein, partialHomo sapiens (human)Potency0.14130.02827.055915.8489AID895; AID928
pyruvate kinaseLeishmania mexicana mexicanaPotency10.00000.398113.744731.6228AID945; AID959
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.15850.039816.784239.8107AID995
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency17.77220.00106.000935.4813AID943; AID944
pyruvate kinase PKM isoform bHomo sapiens (human)Potency15.84892.511912.262825.1189AID954; AID958
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
4-aminobutyrate aminotransferase, mitochondrialSus scrofa (pig)Ki0.30000.30001.25002.2000AID73487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
4-aminobutyrate aminotransferase, mitochondrialSus scrofa (pig)Kd0.46000.46001.63002.8000AID73484
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID73484The Dissociation Constant for Gamma-amino-N-butyrate transaminase1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Slow-binding inhibition of gamma-aminobutyric acid aminotransferase by hydrazine analogues.
AID73487Inhibitory activity against Gamma-amino-N-butyrate transaminase1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Slow-binding inhibition of gamma-aminobutyric acid aminotransferase by hydrazine analogues.
AID73480Dissociation constant of the Gamma-amino-N-butyrate transaminase1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Slow-binding inhibition of gamma-aminobutyric acid aminotransferase by hydrazine analogues.
AID73479Inhibitory rate constant against Gamma-amino-N-butyrate transaminase1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Slow-binding inhibition of gamma-aminobutyric acid aminotransferase by hydrazine analogues.
AID73493The Reactivation Kinetic Constant for Gamma-amino-N-butyrate transaminase1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Slow-binding inhibition of gamma-aminobutyric acid aminotransferase by hydrazine analogues.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (269)

TimeframeStudies, This Drug (%)All Drugs %
pre-199091 (33.83)18.7374
1990's117 (43.49)18.2507
2000's41 (15.24)29.6817
2010's19 (7.06)24.3611
2020's1 (0.37)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.69 (24.57)
Research Supply Index5.61 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (0.73%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other271 (99.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]